Serological Evidence of Hepatitis B and E and Dengue Coinfection in Chadian Patients and Impact on Lipidemia Profile

Objective. Viral hepatitis is an endemic disease in Chad. However, few studies have documented coinfection cases and their impact on cardiovascular risk. This study is aimed at analyzing hepatitis B, E and dengue coinfection in a Chadian cohort and gauge its effect on lipidemia. Patients and Methods...

Full description

Saved in:
Bibliographic Details
Main Authors: Alexandre Kanga Djasrabe, Borris Rosnay Tietcheu Galani, Moussa Mahamat Ali, Fissou Henry Yandai, Bessimbaye Nadlaou, Mayann Habkreo, Nicolas Yanou Njintang
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:International Journal of Hepatology
Online Access:http://dx.doi.org/10.1155/2022/8373061
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832555222669459456
author Alexandre Kanga Djasrabe
Borris Rosnay Tietcheu Galani
Moussa Mahamat Ali
Fissou Henry Yandai
Bessimbaye Nadlaou
Mayann Habkreo
Nicolas Yanou Njintang
author_facet Alexandre Kanga Djasrabe
Borris Rosnay Tietcheu Galani
Moussa Mahamat Ali
Fissou Henry Yandai
Bessimbaye Nadlaou
Mayann Habkreo
Nicolas Yanou Njintang
author_sort Alexandre Kanga Djasrabe
collection DOAJ
description Objective. Viral hepatitis is an endemic disease in Chad. However, few studies have documented coinfection cases and their impact on cardiovascular risk. This study is aimed at analyzing hepatitis B, E and dengue coinfection in a Chadian cohort and gauge its effect on lipidemia. Patients and Methods. From February to May 2021, 179 subjects were recruited from the Department of Gastroenterology and Internal Medicine of the National Reference University Hospital of N’Djamena and tested for viral hepatitis markers, including HBsAg and IgM/IgG anti-HEV and dengue infection, using the NS1/IgM/IgG kit. Serum transaminases and biomarkers of lipid profiles were assayed by colorimetry, and atherogenic indexes (AI) and coronary risk (CRI) were calculated. Results. Of the 179 subjects surveyed, 21.22% (38/179) tested positive for hepatitis B, 20% (27/135) for hepatitis E, and 1.66% (2/120) for dengue. However, most of the patients were found to be asymptomatic. Hepatitis B/E coinfection was more frequent in the study population (5.02%; 9/179) than dengue/hepatitis E coinfection (0.83%; 1/120; IgM). The prevalence of anti-HEV IgG antibodies was higher (18.52%) than that of IgM (1.48%). Furthermore, IgG antibodies levels in HEV-monoinfected subjects (11.05±1.93 IU/mL, N=15) were significantly higher (p<0.05) than in coinfected patients (5.40±1.31 IU/mL, N=9). Subjects coinfected with HEV/HBV were associated with a significantly higher risk of lipodystrophy (coronary risk: 88.89% vs. 35.3%, relative risk RR=2.55; p=0.014), than HEV-monoinfected subjects, as evidenced by higher mean levels of triglycerides levels (219.88±14.67 mg/dL vs. 191.82±4.66  mg/dL, p<0.05), more reduced HDL-C levels (9.05±1.62 mg/dL vs. 18.93±2.35 mg/dL, p<0.05), increased mean CRI (13.81±2.39 vs. 6.89±1.93, p<0.01), and AI (1.46±0.10 vs. 1.05±0.05, p<0.01) values. However, they had normal transaminase values and a lower risk of developing a liver injury, although not significant (alanine aminotransferase: 0% vs. 29.4%, RR=1, p=0.128; aspartate aminotransferase: 0% vs. 5.88%, p=1) than this group. Conclusion. HBV/HEV coinfection is frequent in the Chadian cohort and associated with an important risk of dyslipidemia. Further research is required to elucidate the mechanism of action.
format Article
id doaj-art-3b4b2e3a6701468f8b3eb16014a15004
institution Kabale University
issn 2090-3456
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
series International Journal of Hepatology
spelling doaj-art-3b4b2e3a6701468f8b3eb16014a150042025-02-03T05:49:19ZengWileyInternational Journal of Hepatology2090-34562022-01-01202210.1155/2022/8373061Serological Evidence of Hepatitis B and E and Dengue Coinfection in Chadian Patients and Impact on Lipidemia ProfileAlexandre Kanga Djasrabe0Borris Rosnay Tietcheu Galani1Moussa Mahamat Ali2Fissou Henry Yandai3Bessimbaye Nadlaou4Mayann Habkreo5Nicolas Yanou Njintang6Laboratory of Applied BiochemistryLaboratory of Applied BiochemistryDepartment of Gastroenterology and Internal MedicineLaboratoire Mobile Des Virus Hémorragiques et RespiratoiresLaboratories DepartmentDepartment of Gastroenterology and Internal MedicineLaboratory of Applied BiochemistryObjective. Viral hepatitis is an endemic disease in Chad. However, few studies have documented coinfection cases and their impact on cardiovascular risk. This study is aimed at analyzing hepatitis B, E and dengue coinfection in a Chadian cohort and gauge its effect on lipidemia. Patients and Methods. From February to May 2021, 179 subjects were recruited from the Department of Gastroenterology and Internal Medicine of the National Reference University Hospital of N’Djamena and tested for viral hepatitis markers, including HBsAg and IgM/IgG anti-HEV and dengue infection, using the NS1/IgM/IgG kit. Serum transaminases and biomarkers of lipid profiles were assayed by colorimetry, and atherogenic indexes (AI) and coronary risk (CRI) were calculated. Results. Of the 179 subjects surveyed, 21.22% (38/179) tested positive for hepatitis B, 20% (27/135) for hepatitis E, and 1.66% (2/120) for dengue. However, most of the patients were found to be asymptomatic. Hepatitis B/E coinfection was more frequent in the study population (5.02%; 9/179) than dengue/hepatitis E coinfection (0.83%; 1/120; IgM). The prevalence of anti-HEV IgG antibodies was higher (18.52%) than that of IgM (1.48%). Furthermore, IgG antibodies levels in HEV-monoinfected subjects (11.05±1.93 IU/mL, N=15) were significantly higher (p<0.05) than in coinfected patients (5.40±1.31 IU/mL, N=9). Subjects coinfected with HEV/HBV were associated with a significantly higher risk of lipodystrophy (coronary risk: 88.89% vs. 35.3%, relative risk RR=2.55; p=0.014), than HEV-monoinfected subjects, as evidenced by higher mean levels of triglycerides levels (219.88±14.67 mg/dL vs. 191.82±4.66  mg/dL, p<0.05), more reduced HDL-C levels (9.05±1.62 mg/dL vs. 18.93±2.35 mg/dL, p<0.05), increased mean CRI (13.81±2.39 vs. 6.89±1.93, p<0.01), and AI (1.46±0.10 vs. 1.05±0.05, p<0.01) values. However, they had normal transaminase values and a lower risk of developing a liver injury, although not significant (alanine aminotransferase: 0% vs. 29.4%, RR=1, p=0.128; aspartate aminotransferase: 0% vs. 5.88%, p=1) than this group. Conclusion. HBV/HEV coinfection is frequent in the Chadian cohort and associated with an important risk of dyslipidemia. Further research is required to elucidate the mechanism of action.http://dx.doi.org/10.1155/2022/8373061
spellingShingle Alexandre Kanga Djasrabe
Borris Rosnay Tietcheu Galani
Moussa Mahamat Ali
Fissou Henry Yandai
Bessimbaye Nadlaou
Mayann Habkreo
Nicolas Yanou Njintang
Serological Evidence of Hepatitis B and E and Dengue Coinfection in Chadian Patients and Impact on Lipidemia Profile
International Journal of Hepatology
title Serological Evidence of Hepatitis B and E and Dengue Coinfection in Chadian Patients and Impact on Lipidemia Profile
title_full Serological Evidence of Hepatitis B and E and Dengue Coinfection in Chadian Patients and Impact on Lipidemia Profile
title_fullStr Serological Evidence of Hepatitis B and E and Dengue Coinfection in Chadian Patients and Impact on Lipidemia Profile
title_full_unstemmed Serological Evidence of Hepatitis B and E and Dengue Coinfection in Chadian Patients and Impact on Lipidemia Profile
title_short Serological Evidence of Hepatitis B and E and Dengue Coinfection in Chadian Patients and Impact on Lipidemia Profile
title_sort serological evidence of hepatitis b and e and dengue coinfection in chadian patients and impact on lipidemia profile
url http://dx.doi.org/10.1155/2022/8373061
work_keys_str_mv AT alexandrekangadjasrabe serologicalevidenceofhepatitisbandeanddenguecoinfectioninchadianpatientsandimpactonlipidemiaprofile
AT borrisrosnaytietcheugalani serologicalevidenceofhepatitisbandeanddenguecoinfectioninchadianpatientsandimpactonlipidemiaprofile
AT moussamahamatali serologicalevidenceofhepatitisbandeanddenguecoinfectioninchadianpatientsandimpactonlipidemiaprofile
AT fissouhenryyandai serologicalevidenceofhepatitisbandeanddenguecoinfectioninchadianpatientsandimpactonlipidemiaprofile
AT bessimbayenadlaou serologicalevidenceofhepatitisbandeanddenguecoinfectioninchadianpatientsandimpactonlipidemiaprofile
AT mayannhabkreo serologicalevidenceofhepatitisbandeanddenguecoinfectioninchadianpatientsandimpactonlipidemiaprofile
AT nicolasyanounjintang serologicalevidenceofhepatitisbandeanddenguecoinfectioninchadianpatientsandimpactonlipidemiaprofile